Supernus Shares Tumble 20% After Depression Study Misses Endpoint
Shares of Supernus slid after the company it failed to meet the primary endpoint in its Phase 2b study of SPN-820 in adults with treatment resistant depression.
The stock was down 20% in premarket trading Wednesday. This biopharmaceutical company's stock is up 9.9% this year.
Supernus said results from the study didn't demonstrate statistically significant improvement on the primary endpoint of reduction in depressive symptoms compared to a placebo. The company added SPN-820 was well-tolerated with few adverse events.
President and Chief Executive Officer Jack Khattar said Supernus will continue to analyze data from the study and discuss the program's future with its development partner Navitor Pharmaceuticals.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。
热议股票
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10